BERKELEY, Calif.--(BUSINESS WIRE)--Dynavax Technologies Corporation (Nasdaq:DVAX), a clinical-stage biotechnology company, announced today that Nasdaq has approved the Company’s request to transfer the listing of its shares to The Nasdaq Capital Market from The Nasdaq Global Market effective November 26, 2008.
